Woman aged 50–75 are invited for biennial screening with additional annual screening programs for patients with a cumulative life time risk of breast cancer of over 20% (40–50 years) and BRCA1/2-mutation carriers (25–75 years). The gene discussed is BRCA1; the disease is breast carcinoma.